What is the 13F Pro Quality Score for MDGL?

13F Pro ranks MADRIGAL PHARMACEUTICALS, INC. (MDGL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MDGL's current score at https://13fpro.ai/company/MDGL (free sign-up required for the full ranking).

Which hedge funds own the most MDGL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MDGL include BAKER BROS. ADVISORS, RTW INVESTMENTS,, Jupiter Topco. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/MDGL as soon as new 13F filings post.

Where does 13F Pro source MDGL data?

All MADRIGAL PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. MADRIGAL PHARMACEUTICALS, INC. files with the SEC under CIK 1157601. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MDGL in?

MADRIGAL PHARMACEUTICALS, INC. (MDGL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MDGL research updated on 13F Pro?

MDGL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MADRIGAL PHARMACEUTICALS, INC.(MDGL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1157601 MDGL stock profile & AI dashboard →

13F Pro Quality Score

40.7/100

Rank #2,092 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

99.3/100

Profitability

15.9/100

Balance Sheet

8.2/100

Earnings Quality

30.8/100

Free Cash Flow

14.3/100

Institutional Flow

45.1/100

Revenue Scale

54.9/100

Dilution Risk

4.4/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why MDGL Scores 41/100

exact factor attribution · 2026-09-11

MDGL's composite is driven by revenue growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.9 pts

99th pct

Scale

+0.7 pts

55th pct

Institutional flow

-0.2 pts

45th pct

Earnings growth

-0.8 pts

33th pct

Earnings quality

-1.9 pts

31th pct

Shareholder dilution

-2.3 pts

4th pct

Capital efficiency

-4.2 pts

8th pct

Profitability

-5.1 pts

16th pct

Free cash flow

-5.4 pts

14th pct

Latest change (2026-07-30): 25 → 28 · ↑ Dilution 4→18

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

MDGL Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for MADRIGAL PHARMACEUTICALS, INC. (MDGL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MDGL at 40.7/100 on a 32-signal composite quality model, placing it at rank #2,092 of 2,961 stocks — the bottom half of the AI-ranked universe. MDGL scores in the top quartile across revenue growth (99.3). Areas of concern include balance sheet strength (8.2) and free cash flow (14.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), MADRIGAL PHARMACEUTICALS, INC. reports quarterly revenue of $364.3M, net income of $-57.9M, free cash flow of $19.1M. Top institutional holders of MDGL by reported 13-F value include BAKER BROS. ADVISORS, RTW INVESTMENTS, Jupiter Topco, based on the most recent SEC filings. MDGL trades on the Nasdaq exchange and files with the SEC under CIK 1157601. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MDGL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MADRIGAL PHARMACEUTICALS, INC. directly from SEC EDGAR. MADRIGAL PHARMACEUTICALS, INC.'s 13F Pro composite quality score has ranged between 17 and 41 since 2025, currently 40.7 — an improving long-term trajectory across 52 quarterly and live scoring snapshots.

✦

Fun facts about MADRIGAL PHARMACEUTICALS, INC.

Quirks, history, and lore behind MDGL — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Pennsylvania.
2
The Numbers
For years it burned cash with no approved products, then its first commercial launch sent the stock up hundreds of percent in a single year — from obscurity to Wall Street darling overnight.
3
The History
Founded in the early 2000s, it spent nearly two decades quietly running clinical trials before finally cracking one of liver disease's most stubborn problems.
4
The Secret
Its entire bet is on thyroid hormone receptor beta agonism — a precise mechanism designed to target the liver without the heart side effects that sank earlier drugs in the class.
5
The Lore
Its lead drug, resmetirom, became the first FDA-approved treatment for MASH (metabolic dysfunction-associated steatohepatitis) — a disease affecting tens of millions Americans with virtually no prior options.
6
The Giveaway
One drug, one disease, one historic approval: Rezdiffra for MASH — launched in 2024 by a small Pennsylvania pharma that finally gave fatty liver disease its first-ever medicine.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$364.3M

Net Income

Q2 2026

$-57.9M

Free Cash Flow

Q2 2026

$19.1M

ROIC

Q2 2026

-26.1%

D/E Ratio

Q2 2026

0.65

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+432.1% YoY

$958.4MFY 2025

FY22 $0.00FY23 $0.00FY24 $180.1MFY25 $958.4M

Net Income

+38.1% YoY

$-288.3MFY 2025

FY22 $-295.4MFY23 $-373.6MFY24 $-465.9MFY25 $-288.3M

Operating Income

+39.7% YoY

$-300.1MFY 2025

FY22 $-293.6MFY23 $-380.5MFY24 $-497.9MFY25 $-300.1M

EPS (Diluted)

+41.3% YoY

$-12.85FY 2025

FY22 $-17.23FY23 $-19.99FY24 $-21.90FY25 $-12.85

Total Assets

+20.9% YoY

$1.26BFY 2025

FY22 $362.6MFY23 $640.5MFY24 $1.04BFY25 $1.26B

Total Debt

+189.1% YoY

$339.9MFY 2025

FY22 $69.7MFY23 $115.5MFY24 $117.6MFY25 $339.9M

Op. Cash Flow

+58.4% YoY

$-189.6MFY 2025

FY22 $-224.9MFY23 $-324.2MFY24 $-455.6MFY25 $-189.6M

Free Cash Flow

+58.4% YoY

$-190.0MFY 2025

FY22 $-225.1MFY23 $-325.7MFY24 $-457.0MFY25 $-190.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$958.4M +432.1%	$180.1M	$0.00	$0.00	$0.00	$0.00
Net Income	$-288.3M +38.1%	$-465.9M -24.7%	$-373.6M -26.5%	$-295.4M -22.1%	$-241.8M -19.6%	$-202.2M
Operating Income	$-300.1M +39.7%	$-497.9M -30.8%	$-380.5M -29.6%	$-293.6M -21.1%	$-242.5M -17.3%	$-206.7M
EPS (Diluted)	$-12.85 +41.3%	$-21.90 -9.6%	$-19.99 -16.0%	$-17.23 -17.8%	$-14.63 -11.8%	$-13.09
Total Assets	$1.26B +20.9%	$1.04B +62.7%	$640.5M +76.7%	$362.6M +32.6%	$273.3M -4.8%	$287.0M
Total Debt	$339.9M +189.1%	$117.6M +1.8%	$115.5M +65.7%	$69.7M	$0.00	—
Operating Cash Flow	$-189.6M +58.4%	$-455.6M -40.5%	$-324.2M -44.2%	$-224.9M -22.3%	$-183.9M -16.7%	$-157.6M
Free Cash Flow	$-190.0M +58.4%	$-457.0M -40.3%	$-325.7M -44.7%	$-225.1M -22.2%	$-184.1M -16.6%	$-157.9M

Get alerted when MDGL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MADRIGAL PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MDGL

BAKER BROS. ADVISORS LP
$1.2B2,143,131 sh
RTW INVESTMENTS, LP
$1.1B1,993,687 sh
Jupiter Topco LLC
$1.0B1,936,099 sh
Avoro Capital Advisors LLC
$984.4M1,833,333 sh
PAULSON & CO. INC.
$719.5M1,340,020 sh
BlackRock, Inc.
$644.8M1,200,770 sh
VANGUARD CAPITAL MANAGEMENT LLC
$448.7M835,668 sh
WELLINGTON MANAGEMENT GROUP LLP
$443.4M825,714 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$419.8M781,731 sh
STATE STREET CORP
$283.0M527,057 sh

Fund	Value	Shares
BAKER BROS. ADVISORS LP	$1.2B	2,143,131
RTW INVESTMENTS, LP	$1.1B	1,993,687
Jupiter Topco LLC	$1.0B	1,936,099
Avoro Capital Advisors LLC	$984.4M	1,833,333
PAULSON & CO. INC.	$719.5M	1,340,020
BlackRock, Inc.	$644.8M	1,200,770
VANGUARD CAPITAL MANAGEMENT LLC	$448.7M	835,668
WELLINGTON MANAGEMENT GROUP LLP	$443.4M	825,714
VANGUARD PORTFOLIO MANAGEMENT LLC	$419.8M	781,731
STATE STREET CORP	$283.0M	527,057

Companies Similar to MDGL

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

INSM

INSMED Inc

AI score

Very similar · 29 shared holders

BAKER BROS. ADVISORS LP RTW INVESTMENTS, LP Artisan Partners Limited Partnership

BBIO

BridgeBio Pharma, Inc.

AI score

Very similar · 30 shared holders

Polar Capital Holdings Plc Hood River Capital Management LLC LORD, ABBETT & CO. LLC

ARWR

ARROWHEAD PHARMACEUTICALS, INC.

AI score

Very similar · 29 shared holders

Avoro Capital Advisors LLC BAKER BROS. ADVISORS LP Hood River Capital Management LLC

MIRM

Mirum Pharmaceuticals, Inc.

AI score

Very similar · 27 shared holders

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Polar Capital Holdings Plc Rock Springs Capital Management LP

RYTM

RHYTHM PHARMACEUTICALS, INC.

AI score

Very similar · 30 shared holders

BAKER BROS. ADVISORS LP Polar Capital Holdings Plc Rock Springs Capital Management LP

Guardant Health, Inc.

AI score

Very similar · 23 shared holders

RTW INVESTMENTS, LP WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC LORD, ABBETT & CO. LLC

CYTK

CYTOKINETICS INC

AI score

Very similar · 27 shared holders

Avoro Capital Advisors LLC RTW INVESTMENTS, LP ARMISTICE CAPITAL, LLC

AXSM

Axsome Therapeutics, Inc.

AI score

Very similar · 27 shared holders

Hood River Capital Management LLC Clearbridge Investments, LLC DRIEHAUS CAPITAL MANAGEMENT LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MDGL on your watchlist

Track score changes the day MADRIGAL PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MDGL a good stock to buy?

13F Pro's AI-powered analysis of MADRIGAL PHARMACEUTICALS, INC. (MDGL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MDGL are available on the MDGL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MDGL is classified as a large company.

Which hedge funds own MDGL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MDGL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MADRIGAL PHARMACEUTICALS, INC.'s investment landscape.